Activation of the Type I Interferon Pathway in Primary Sjögren's Syndrome: an Update

Overview

Journal Curr Opin Rheumatol

Specialty Rheumatology

Date 2011 Jul 16

PMID 21760509

Citations 25

Authors

Katerina M Vakaloglou

Clio P Mavragani

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Recent advances suggest type I interferon (IFN) pathway as an emerging mediator of systemic autoimmunity. This review aims to summarize the latest developments in the biology of type I IFN pathway and its contributory role in the pathogenesis of autoimmune disorders with a particular focus on Sjögren's syndrome.

Recent Findings: Increased circulating type I IFN levels along with upregulated type I IFN inducible genes in salivary gland tissues, peripheral blood and mononuclear cells suggest activation of type I IFN pathway in Sjögren's syndrome. Additional regulatory mechanisms and novel potential suppressors of type I IFN production provide new insights into disease pathogenesis, pointing to type I IFN system as a potential new therapeutic target.

Summary: Compelling evidence suggests type I IFN as a key player in pathogenesis of Sjögren's syndrome and an attractive potential therapeutic target. Meticulous stratification of patient subgroups characterized by activation of type I IFN pathway should be performed in carefully designed translational studies.

Citing Articles

Identification of Epigenetic Alteration of the IFI44L Gene in B Cells of Sjogren's Syndrome as a Clinical Biomarker and Molecular Significance.

Zhang K, Luo Z, Yao X, Lu D, Hong T, Zhu X J Inflamm Res. 2025; 18:2499-2512.

PMID: 39991660 PMC: 11847453. DOI: 10.2147/JIR.S503309.

Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome.

Huang J, Tang J, Zhang C, Liu T, Deng Z, Liu L J Transl Autoimmun. 2024; 9:100248.

PMID: 39131726 PMC: 11314884. DOI: 10.1016/j.jtauto.2024.100248.

Oral Administration of Vitamin D3 Prevents Corneal Damage in a Knock-Out Mouse Model of Sjögren's Syndrome.

Trotta M, Herman H, Balta C, Rosu M, Ciceu A, Mladin B Biomedicines. 2023; 11(2).

PMID: 36831152 PMC: 9953695. DOI: 10.3390/biomedicines11020616.

Targeting type I interferons in systemic lupus erythematous.

Bruera S, Chavula T, Madan R, Agarwal S Front Pharmacol. 2023; 13:1046687.

PMID: 36726783 PMC: 9885195. DOI: 10.3389/fphar.2022.1046687.

Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus.

Shen M, Duan C, Xie C, Wang H, Li Z, Li B Front Immunol. 2022; 13:962393.

PMID: 35967341 PMC: 9365928. DOI: 10.3389/fimmu.2022.962393.